

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Study protocol for SPARED trial: Phase III study comparing dexamethasone on day 1 with dexamethasone on day 1-4 combined with neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-based chemotherapy

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041737
Article Type:	Protocol
Date Submitted by the Author:	20-Jun-2020
Complete List of Authors:	<p>Minatogawa, Hiroko; St.Marianna University School of Medicine Hospital, Department of Pharmacy Izawa, Naoki; St. Marianna University School of Medicine, Department of Clinical Oncology Kawaguchi, Takashi; Tokyo University of Pharmacy and Life Sciences, Department of Practical Pharmacy Miyaji, Tempei; University of Tokyo, Shimomura, Kazuhiro; Aichi Cancer Center Hospital Kazunori, Honda; Aichi Cancer Center Hospital, Department of Clinical Oncology Iihara, Hirotooshi; Gifu University Hospital, Pharmacy Ohno, Yasushi; Gifu University School of Medicine Graduate School of Medicine, Department of Cardiology and Respiriology Inada, Yusuke; Yokohama Rosai Hospital, Department of Pharmacy Arioka, Hitoshi; Yokohama Rosai Hospital, Department of Medical Oncology Morita, Hajime; St. Marianna University Yokohama City Seibu Hospital, Department of Pharmacy Hida, Naoya; St.Marianna University School of Medicine, 12. Department of Internal Medicine Sugawara, Mitsuhiro; Kitasato University Hospital, 13. Department of Pharmacy Katada, Chikatoshi; Kitasato University School of Medicine, Department of Gastroenterology Nawata, Shuichi; Showa University Northern Yokohama Hospital, Department of Hospital Pharmaceutics Ishida, Hiroo; Showa University Northern Yokohama Hospital, Department of Internal Medicine Tsuboya, Ayako; Kawasaki Municipal Tama Hospital Tsuda, Takashi; St. Marianna University School of Medicine, Department of Clinical Oncology; Shonan Fujisawa Tokushukai Hospital, Department of Hepato-Biliary-Pancreatic Center Yamaguchi, Takuhiro; Tohoku University School of Medicine, Division of Biostatistics Nakajima, Takako; St. Marianna University School of Medicine, Department of Clinical Oncology,; Kyoto University Hospital, Division of Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Therapy
Keywords:	CHEMOTHERAPY, Adult palliative care < PALLIATIVE CARE, Clinical trials < THERAPEUTICS, Adverse events < THERAPEUTICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title

Study protocol for SPARED trial: Phase III study comparing dexamethasone on day 1 with dexamethasone on day 1-4 combined with neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-based chemotherapy

Authors' name

Hiroko Minatogawa¹, Naoki Izawa², Takashi Kawaguchi³, Tempei Miyaji⁴, Kazuhiro Shimomura⁵, Kazunori Honda⁶, Hirotoishi Iihara⁷, Yasushi Ohno⁸, Yusuke Inada⁹, Hitoshi Arioka¹⁰, Hajime Morita¹¹, Naoya Hida¹², Mitsuhiro Sugawara¹³, Chikatoshi Katada¹⁴, Shuichi Nawata¹⁵, Hiroo Ishida¹⁶, Ayako Tsuboya¹⁷, Takashi Tsuda^{2,18}, Takuhiro Yamaguchi¹⁹, Takako Eguchi Nakajima^{2,20}

Authors' Affiliation

1. Department of Pharmacy, St.Marianna University School of Medicine Hospital, Kawasaki, Japan
2. Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan
3. Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
4. Department of Clinical Trial Data Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
5. Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan

- 1
- 2
- 3
- 4
- 5
- 6 6. Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
- 7
- 8 7. Department of Pharmacy, Gifu University Hospital, Gifu, Japan
- 9
- 10 8. Department of Respiriology, Gifu University Graduate School of Medicine, Gifu,
- 11 Japan
- 12
- 13 9. Department of Pharmacy, Yokohama Rosai Hospital, Yokohama, Japan
- 14
- 15 10. Department of Medical Oncology, Yokohama Rosai Hospital, Yokohama, Japan
- 16
- 17 11. Department of Pharmacy, St. Marianna University Yokohama City Seibu Hospital,
- 18 Yokohama, Japan
- 19
- 20 12. Department of Internal Medicine, St. Marianna University School of Medicine,
- 21 Kawasaki, Japan
- 22
- 23 13. Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan
- 24
- 25 14. Department of Gastroenterology, Kitasato University School of Medicine,
- 26 Sagamihara, Japan
- 27
- 28 15. Department of Hospital Pharmaceutics, Showa University Northern Yokohama
- 29 Hospital, Yokohama, Japan
- 30
- 31 16. Department of Internal Medicine, Showa University Northern Yokohama Hospital,
- 32 Yokohama, Japan
- 33
- 34 17. Department of Pharmacy, St. Marianna University Kawasakishi Municipal Tama
- 35 Hospital, Kawasaki, Japan
- 36
- 37 18. Department of Hepato-Biliary-Pancreatic Center, Shonan Fujisawa Tokushukai
- 38 Hospital, Fujisawa, Japan
- 39
- 40 19. Division of Biostatistics, Tohoku University School of Medicine, Sendai, Japan
- 41
- 42 20. Division of Kyoto Innovation Center for Next Generation Clinical Trials and iPS
- 43 Cell Therapy, Kyoto University Hospital, Kyoto, Japan
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Corresponding author

Takako Eguchi Nakajima, M.D., Ph.D.

Division of Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell

Therapy, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku Kyoto, 606-

8507, Japan

E-mail: tnakajima@kuhp.kyoto-u.ac.jp

Tel: +81-75-751-3111 (4756)

Fax: +81-75-751-4732

Key words

Nausea, Vomiting, Dexamethasone, Olanzapine, Cisplatin

Word count

3359 words

Abstract

Introduction

Dexamethasone (DEX) is administered for multiple days to prevent chemotherapy-induced nausea and vomiting (CINV) for patients receiving highly emetogenic chemotherapy (HEC); however, its notorious side effects have been widely reported. Although our multicenter randomized double-blind comparative study verified non-inferiority of sparing DEX after day 2 of chemotherapy when combined with neurokinin-1 receptor antagonist (NK1-RA) and palonosetron (Palo) for patients receiving HEC regimen, DEX sparing was not non-inferior in patients receiving cisplatin (CDDP)-based HEC regimens in subgroup analysis. Recently, the efficacy of the addition of olanzapine (OLZ) to standard triple antiemetic therapy on HEC has been demonstrated by several phase III trials. This study aims to confirm non-inferiority of DEX sparing when it is combined with NK-1RA, Palo, and OLZ in patients receiving CDDP-based HEC regimens.

Methods and analysis

This is a randomized, double-blind, phase III trial. Patients who are scheduled to receive CDDP $\geq 50\text{mg}/\text{m}^2$ as initial chemotherapy are eligible. Patients are randomly assigned to receive either DEX on day 1 to 4 or DEX on day 1 combined with NK1-RA, Palo, and OLZ (5mg). The primary endpoint is complete response (CR) rate, defined as no emesis and no rescue medications during the delayed phase (24 to 120 hours post-CDDP administration). The non-inferiority margin is set at -15.0%. We assume that CR rates would be 75% in both arms. Two hundred sixty-two patients are required for at least

1
2
3
4
5
6 80% power to confirm non-inferiority at a one-sided significance level of 2.5%. After
7
8 considering the possibility of attrition, we set our final required sample size of 280.
9

10 11 **Ethics and dissemination**

12
13
14
15 The institutional review board approved the study protocol at each of the participating
16
17 centers. The trial result will be presented at international conferences and published in
18
19 peer-reviewed journals.
20
21

22 23 **Trial registration number**

24
25
26 UMIN000032269
27
28

29 30 **Protocol version**

31
32
33 3.0, 24 May 2020.
34
35

36 37 **Strengths and limitations of this study**

- 38
39 ➤ This is the first trial to evaluate whether adding olanzapine to neurokinin-1 receptor
40
41 antagonist, palonosetron (Palo), and dexamethasone (DEX) can spare DEX
42
43 administration on day 2 to 4 for patients receiving cisplatin-based regimens.
44
45 ➤ This study is a multicenter, placebo-controlled, double-blinded, randomized phase
46
47 III study.
48
49 ➤ The limitation of this study is that Palo is administered at a dose of 0.75 mg in
50
51 Japan; whereas, international antiemetic guidelines recommend a Palo dose of 0.25
52
53 mg.
54
55
56
57
58
59
60

Introduction

Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent adverse reactions associated with chemotherapy, and considerably reduces patient quality of life (QOL). CINV has been traditionally assessed in overall (0-120 h post-chemotherapy), acute (0-24 h post-chemotherapy), or delayed (24-120 h post-chemotherapy) phases,[1]. Intravenously administered cytotoxic agents are categorized into 4 emetic risk groups (high, moderate, low, and minimal),[2]. Highly emetogenic chemotherapy (HEC) including cisplatin (CDDP)-based regimen and anthracycline plus cyclophosphamide (AC) regimen can lead to a > 90 % incidence of CINV in patients without an adequate antiemetic prophylaxis,[3].

Dexamethasone (DEX), 5-hydroxytryptamine type 3 receptor antagonists (5-HT₃-RA) and neurokinin-1 receptor antagonists (NK1-RA) have been developed to inhibit CINV from HEC,[4-5]. DEX is typically administered for multiple days from the start of chemotherapy to care for delayed CINV,[6];whereas, frequent administration of corticosteroids has been associated with many adverse effects such as insomnia, hyperglycemia and reduced bone mineral density,[7-9]. Our multicenter randomized double-blind comparative study (DEX-1 study) showed the complete response (CR; no emesis, no use of rescue medication) rate in the overall phase of DEX on day 1 provided a non-inferior antiemetic efficacy to a treatment of DEX on day1-3 when combined with NK1-RA and palonosetron (Palo) for patients receiving HEC including AC and CDDP-based regimen. (44.0 % vs. 46.9 %, $P = 0.007$),[10] . In a subgroup analysis of patients receiving CDDP-based regimen, CR rates of acute phase demonstrated a non-inferiority of DEX on day1 to day 1-3 (95.6 % vs 95.6 %, $P = 0.007$); however, CR

1
2
3
4
5
6 rates of the overall and delayed phases DEX on day 1 were lower than those DEX on
7
8 day 1-3 (57.8 % vs 66.7 %, $P = 0.272$; 57.8 % vs 68.9 %, $P = 0.349$, respectively).
9

10 Tamura et al reported that the incidence of CINV for the patients receiving CDDP-
11
12 based regimen peaked on day 4 to 5,[11]. Therefore, some guidelines still recommend
13
14 multiple-days DEX in combination with 5-HT₃-RA and NK1-RA for CDDP-based
15
16 regimens,[3, 12-14].
17
18

19
20
21 Olanzapine (OLZ) is classified as a multi-acting receptor-targeted antipsychotic
22
23 and blocks dopamine receptors (D₁, D₂, D₄), 5-HT receptors (5-HT_{2A}, 5-HT_{2C}, 5-HT₃),
24
25 α_1 adrenergic receptors, histamine receptors, and multiple muscarine receptors,[15],
26
27 which might affect CINV. In the randomized, double-blind, phase III trial involving
28
29 patients receiving HEC regimens, it was more effective to combine OLZ 10mg than
30
31 placebo with NK1-RA, 5-HT₃-RA, and DEX for the prevention of nausea and vomiting
32
33 in acute and delayed phases,[16]; however, OLZ (10mg) had excessive sedation.
34
35

36 Therefore, it is difficult to use OLZ 10mg for all patients in practice setting. Recently, J-
37
38 FORCE study, which was a randomized, double-blind, placebo-controlled phase III trial
39
40 evaluating the significance of adding of 5mg OLZ to NK1-RA, Palo, and DEX in
41
42 CDDP-based regimens, showed that significantly more patients receiving OLZ achieved
43
44 CR from delayed CINV compared with those who received placebo (79 % versus 66%,
45
46 $P < 0.001$); moreover, no differences were found between two groups in the incidence
47
48 of sedation,[17]. The addition of OLZ in combination with NK1-RA, Palo, and DEX
49
50 has greater benefit and becomes a standard antiemetic therapy in patients receiving
51
52 CDDP-based regimens.
53
54

55
56
57 Treatment with OLZ was associated with metabolic effects, including elevated
58
59 glucose concentrations manifesting as insulin resistance,[18]. A phase III study showed
60

1
2
3
4
5
6 that grade 3 hyperglycemia was observed more frequently in the OLZ versus placebo
7
8 group,[16]. Therefore, there is a concern that the combination of OLZ and multiple-days
9
10 DEX may worsen glucose intolerance. In another study, Navari et al. also demonstrated
11
12 that OLZ, combined with a single dose of DEX and Palo was very effective at
13
14 controlling acute and delayed phase CINV in patients receiving HEC; moreover, this
15
16 regimen was not associated with significant hyperglycemia,[19].
17
18

19
20 Based on these results, we speculate that the antiemetic regimen of OLZ 5mg,
21
22 NK1-RA, Palo, and a single dose of DEX could be effective and safe for delayed phase
23
24 CINV in patients receiving CDDP-based regimen. We planned this randomized, double-
25
26 blind, phase III trial to evaluate the non-inferiority of DEX on day1 compared with
27
28 DEX on day1 to 4 when combined with NK1-RA, Palo, and OLZ in patients receiving
29
30 CDDP-based regimens.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods and Analysis

Study Design

The Standard Protocol Items for Randomized Trials (SPIRIT) statement and checklist were followed in preparing the protocol. This multicenter, placebo-controlled, double-blinded, randomized, non-inferiority, phase III study aims to confirm the non-inferiority of DEX on day 1 compared to DEX on days 1 to 4 combined with NK1-RA, Palo and OLZ 5mg to prevent CINV in patients with solid malignant tumor receiving CDDP-based regimens.

Study setting and participants

Recruiting will be performed in 10 sites across Japan. The inclusion and exclusion criteria are summarized in box 1.

Box.1

Inclusion criteria

- I. Patients with malignant tumor, excluding hematologic malignancies, receiving first-line treatment with CDDP $\geq 50\text{mg/m}^2$.
- II. Aged: 20-74 years at registration
- III. Absence of nausea and vomiting within 24 hours prior to registration.
- IV. Eastern Cooperative Oncology Group performance status of 0-1.

1
2
3
4
5
6 V. Meeting the following standard vales of general clinical tests within 2 weeks prior to
7
8 enrolment:

- 9
10 a. alanine aminotransferase < 100 IU/L.
11
12 b. aspartate aminotransferase < 100 IU/L.
13
14 c. total bilirubin < 2.0 mg/dL.
15
16 d. serum creatinine < 1.5 mg/dL.
17
18

19 VI. Patients with expected prognosis of 3 months or more.

20
21 VII. Patients who provided written informed consent.
22
23
24
25

26 **Exclusion criteria**

- 27
28 I. Presence of systemic glucocorticoid therapy.
29
30 II. Patients using antiemetics other than the trial drug.
31
32 III. Patients receiving moderately emetogenic chemotherapy within 6 days before and
33
34 after CDDP administration.
35
36 IV. Patients who cannot be hospitalized until after 120 hours have passed since starting
37
38 CDDP administration.
39
40 V. Patients receiving radiation therapy to abdomen or pelvis within 6 days prior to
41
42 enrolment until six days after CDDP administration.
43
44 VI. Presence of diabetes mellitus receiving treatment with insulin and/ or oral
45
46 hypoglycemic agents, or patients with HbA1c (NGSP) > 6.5 % (> 6.1 % in the event
47
48 of JDS).
49
50 VII. Presence of symptomatic brain metastasis, convulsive disorder requiring treatment
51
52 with anticonvulsants, and mental illness or psychiatric symptoms that impede
53
54 activities of daily life.
55
56
57
58
59
60

VIII. Patients who are incapable of taking oral agents.

IX. History of allergy to study drugs or similar compounds.

X. Breastfeeding, pregnant women, or patients not willing to use contraception.

XI. Patients deemed inappropriate for the study by the investigator.

The main inclusion criterion is patients who are eligible in the study are 20 to 74 years old with malignant tumor, excluding hematological malignancies, receiving first-line treatment with CDDP ≥ 50 mg/m² (previous use of moderately or low emetogenic chemotherapy is permitted). The main exclusion criteria are as followed: (1) presence of systemic glucocorticoid therapy; (2) patients using antiemetics other than the trial drug; (3) patients receiving moderately emetogenic chemotherapy within six days before and after CDDP administration (Minimally to low emetogenic agents are allowed); (4) patients receiving radiation therapy to abdomen or pelvis within six days prior to enrollment until six days after CDDP; (5) presence of symptomatic brain metastasis, diabetes mellitus, and convulsive disorder; (6) patients who are incapable of taking oral agents.

Recruitment, randomization, masking, and follow-up

Recruitment

Eligible patients satisfying the screening inclusion and exclusion criteria will be invited to participate in the study by site investigators.

Randomization

Physicians will introduce the trial to patients. On enrolment and after providing informed consent, Eligible patients will be randomly assigned to receive either DEX on day 1 to 4 or DEX on day 1 with placebo on days 2 to 4 as part of prophylactic antiemetic therapy. Randomization is centrally performed by random allocation modules of electronic data captures (EDC) using the minimization method with balancing prognostic factors for age (< 60 vs ≥ 60 years), sex, CDDP dose level ($\geq 70\text{mg/m}^2$ vs $< 70\text{mg/m}^2$), and institution.

Masking

Patients and clinicians responsible for treatment will be blinded to administration of DEX or placebo. Only an unblinded pharmacist who prepares the study drug, but is not involved in patient care will know the assignment and outcome. All study drugs will be prepared by this pharmacist. As a rule, no data will be disclosed until fixed. However, during the trial period, when it is considered necessary to know the details of the trial drug to ensure participant safety, such as for serious adverse events, the study representative and study secretariat will make an inquiry to and discuss the need for disclosure with the Efficacy and Safety Evaluation Committee. When disclosure is deemed necessary as a result of this consultation, the details will be communicated to the study secretariat, and the details of the trial drug will be disclosed.

Data management, central monitoring, and auditing

The data center is located in the Department of Clinical Trial Data Management, Graduate School of Medicine, Tokyo University, Tokyo, Japan. Enrollment, randomization, data collection, and monitoring will be performed using EDC system Viedoc 4 and Viedoc me (Viedoc Technologies). Data entry to the electronic case report form is performed by investigators using EDC at each site. Patient-Reported Outcomes (PRO) data are collected electronically from patients through an electronic tablet device. No personally identifiable information is entered into the EDC, and the data center does not collect personal information. The central monitoring will be conducted by the data center, and monthly and semi-annually monitoring reports will be disseminated to investigators to inform about the trial progress and discuss data quality-related issues. The Protocol Review Committee and independent Data Monitoring Committee will assess the protocol amendments, serious adverse events reports, and monitoring reports and provide any necessary recommendation to investigators. Auditing will be conducted as necessary in this study.

Harms

Investigators must record all adverse events in the medical records and web systems. The Common Terminology Criteria for Adverse Events (CTCAE, v4.0) will be used to grade each adverse event. In conjunction with the CTCAE to grade adverse events, the Patient Reported Outcomes CTCAE (PRO-CTCAE) will be also administered to

1
2
3
4
5
6 patients for their completion to complement information about subjective symptoms.
7

8 All adverse events are to be followed up continually during the course of treatment. All
9 severe adverse events must be reported to the Institutional Review Board (IRB) and
10 reported to investigators in all sites and discussed through a mail. Patients who are
11 enrolled into the study will be treated by the health care services that are provided by
12 their health insurance.
13
14
15
16
17
18
19
20
21
22
23

24 **Treatment**

25
26
27 All patients receive Palo (0.75 mg intravenous infusion on day 1 at 30 min before the
28 start of chemotherapy), NK1-RA (aprepitant 125 mg oral administration on day1 and 80
29 mg on days 2 and 3, or fosaprepitant 150 mg intravenous infusion on day 1 at 1 hour
30 before the start of chemotherapy), and OLZ (5mg oral administration on days 1 to 4
31 after dinner). DEX is administered as follows: patients in both arms receive DEX 9.9
32 mg intravenous infusion on day 1; patients receive DEX 6.6 mg or placebo intravenous
33 infusion on days 2 to 4. When using fosaprepitant, the dose level is increased on days 3
34 and 4 due to interaction with DEX up to day 2, therefore patients receive an intravenous
35 DEX 13.2 mg or placebo on days 3 and 4. Patients were allowed to take rescue
36 medication throughout the study period for nausea or vomiting, if necessary. The choice
37 of recommended rescue is determined by each investigator from among
38 prochlorperazine, metoclopramide, domperidone, chlorpheniramine, alprazolam,
39 lorazepam, and haloperidol.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study Endpoints

The primary endpoint is CR rate (no emesis and no rescue medications) during the delayed phase (24 to 120 hours post-CDDP administration). Secondary endpoints are as follows: (1) CR rate during the acute phase (24 hours post-CDDP administration) and the overall phase (120 hours post-CDDP administration); (2) complete control (CC; no emesis, no rescue use, and no significant nausea) rate; (3) total control (TC; no emesis, no rescue use, and no nausea) rate; (4) no emesis rate and no nausea rate in the overall, acute, and delayed phase; (5) time to treatment failure (i.e., time to first emesis or using rescue, whichever occurred first); and (6) severity of nausea during the overall phase.

Adverse events.

Outcome Assessments

Figure 1 provides details of the schedule of enrolment, interventions and assessments. Presence of emesis and severity of nausea will be assessed by patients using a 2-point categorical scale and 11-point numerical rating scale (NRS), respectively. Significant nausea is defined as 3 points or greater on the NRS. The use of rescue medications will be assessed by pharmacists.

Adverse events will be evaluated according to the CTCAE v4.0 Japanese Clinical Oncology Group (JCOG) version, and the PRO-CTCAE v1.0. The Japanese version of PRO-CTCAE is linguistically and psychometrically validated,[20-21]. Quality of life (QOL) will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) v.3 that is also validated in the Japanese version,[22].

1
2
3
4
5
6 Patients are asked to assess QOL before CDDP administration and on Day 8, with
7
8 emesis and nausea assessed the PRO-CTCAE every 24 hours until 120 hours after
9
10 CDDP administration (figure). The data from the PRO-CTCAE are assessed
11
12 electronically using a tablet device in the hospital setting, except for QOL on Day 8,
13
14 which is assessed on paper-based questionnaire at home. The PRO-CTCAE data will be
15
16 not reviewed by the site investigators during the protocol treatment.
17
18
19
20
21
22

23 **Statistical analysis**

24
25
26 Sample size calculation is based on an analysis of the primary endpoint. In previous
27
28 studies with OLZ added to conventional antiemetic treatment for CDDP,[19, 23-24], the
29
30 delayed phase CR rate ranged from 75% to 85 %, therefore we expect that CR rate in
31
32 the delayed phase would be 75% in both arms. The non-inferiority margin is set at -
33
34 15.0%. Two hundred sixty-two patients are required for at least 80 % power to confirm
35
36 non-inferiority at a one-sided significance level of 2.5 %. After considering the
37
38 possibility of attrition we set our final required sample size of 280. Point estimates and
39
40 confidence intervals for the CR rate will be calculated and will be compared between
41
42 groups by using the Mantel-Haenszel test with adjustment for allocation factors. Interim
43
44 analysis is not planned.
45
46
47
48
49
50
51
52

53 **Patient and public involvement**

54
55
56 Patients and/ or public were not involved in the design of this study.
57
58
59
60

Ethics and dissemination

All patients will be required to provide written informed consent. The study will be performed in accordance with the Declaration of Helsinki and Ethical Guidelines for Medical and Health Research Involving Human Subjects published by Japan's Ministry of Education, Science, and Technology and the Ministry of Health, Labour, and Welfare and the modified Act on the Protection of Personal Information. The protocol was approved by the IRB at each study site. This trial has been registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry as UMIN000032269. Modifications in the study protocol will be communicated to the IRB at each study site as well as to the protocol review committee. Each Ethics Committee or IRB will revise informed consent materials given to participants and adapt the informed consent according to their own institution's guidelines. The main result will be presented at an international conference and published in an English journal. Authorship will be ascribed in accordance with the International Committee of Medical Journal Editors guidance.

Access to data

Only clinical data managers at the central data center have access to collected data through the EDC system during the study. Site investigators have access to case data within their institutions. After study closure, final dataset and related materials will be archived in UMIN Individual Case Data Repository.

Participating institutions

St. Marianna University School of Medicine Hospital, St. Marianna University
Kawasakishi Muncipal Tama Hospital, St. Marianna University Yokohama City Seibu
Hospital, Showa University Northern Yokohama Hospital, Yokohama Rosai Hospital,
Nippon Medical School Musashi Kosugi Hospital, Aichi Cancer Center Hospital, Gifu
University Hospital, Kitasato University Hospital, Shizuoka Cancer Center.

Trial status

This protocol was approved by the Ethics Committee on July 27, 2018. The trial started
in October 2018 and 183 subjects were randomized by May 2020. The recruitment is
scheduled to be completed in March 2021.

Confidentially

Data will be retained in accordance with the Japanese ethical guidelines for clinical
research. Participants will be allocated a unique identification (ID) number at entry. The
master list linking participant personal information and ID number will be managed at
each institution. Data will be analyzed by ID number only. Records will be retained for
5 years after study completion and then will be destroyed at each institution.

Acknowledgement

1
2
3
4
5
6 We are grateful for support from the Japan Agency for Medical Research and
7
8
9 Development, Grant-in-Aid for Scientific Research. The authors thank in advance all
10
11
12 the patients, investigators and institutions involved in this study.
13
14
15
16
17

18 **Authors' contributions**

19
20 H.M, N.I, T.K, T.M, T.Y and T.EN participated in the design of the study. T.K, T.M
21
22 and T.Y designed the statistical analysis plan. All authors contributed to writing and
23
24 revising the manuscript critically, and all gave their final approval of the version to be
25
26
27 published.
28
29
30
31
32
33
34

35 **Funding**

36
37 This study is supported by Japan Agency for Medical Research and Development
38
39 (AMED) grant number 19ck0106501h0001. AMED had and will have no involvement
40
41 in the design and conduct of the study, collection, management, analysis, and
42
43 interpretation of the data; and preparation, review, or approval of the manuscript.
44
45
46
47

48 **Competing interests statement**

49
50 N.I has received honoraria from Takeda Pharma CO., Ltd, Eli Lilly, Japan, Ono Pharma
51
52 CO., Ltd, and Daiichi Sankyo Company. Author H.A has received grant from Taiho,
53
54 Chugai and Nippon Kayaku; personal fees from Novartis, Sanofi, Ono, Kyowa Kirin
55
56 and Takeda. Author T.Y has received grant and personal fees from ONO
57
58
59
60

1
2
3
4
5
6 PHARMACEUTICAL CO., LTD. Author T.N has received grant and personal fee from
7
8 Taiho Pharmaceutical Co., Chugai Pharmaceutical Co., Takeda Pharmaceutical Co.,
9
10 Sanofi K.K., Daiichi Sankyo Co., Eli Lilly Japan K.K., Nippon Kayaku Co., Ono
11
12 Pharmaceutical Co. and MSD K.K.; personal fees from Mochida Pharmaceutical,
13
14 Celltrion Healthcare Japan, Merck Serono Co., Sawai Pharmaceutical Co., Bayer
15
16 Yakuhin, Bristol-Myers Squibb, Teijin Pharma, Pfizer Japan Inc., Novartis Japan,
17
18 Yakult Honsha Co. and Nipro Co; grant from Astellas Pharma Inc., Sumitomo
19
20 Dainippon Pharma Co., Eisai Co and Solasia Pharma K.K.. The other authors have
21
22 declared no conflicts of interest.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. *N Engl J Med* 2016;374(14):1356-67.
2. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. *J Clin Oncol* 1997;15(1):103-9.
3. Japan Society of Clinical Oncology. Antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting: Kanehara shuppan 2015
4. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. *J Clin Oncol* 2003;21(22):4112-9.
5. Gralla RJ, de Wit R, Herrstedt, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. *Cancer* 2005;104(4):864-8.
6. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. *Ann Oncol* 2007;18(2):233-40.
7. J Vardy, Chiew KS, Galica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. *Br J Cancer* 2006;94(7):1011-5.

- 1
2
3
4
5
6 8. Jeong Y, Han HS, Lee HD, et al. A Pilot Study Evaluating Steroid-Induced
7
8 Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated
9
10 Cancer Patients. *Cancer Res Treat* 2016;48(4):1429-1437.
11
- 12
13 9. Nakamura M, Ishiguro A, Muranaka T, et al. Prospective Observational Study
14
15 on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in
16
17 Gastrointestinal Cancer (ESPRESSO-01). *Oncologist* 2017;22(5):592-600.
18
- 19
20 10. Ito Y, Tsuda T, Minatogawa H, et al. Placebo-Controlled, Double-Blinded Phase
21
22 III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1
23
24 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in
25
26 High-Emetogenic Chemotherapy. *J Clin Oncol* 2018;36(10):1000-1006.
27
- 28
29 11. Tamura K, Aiba K, Saeki T, et al. CINV Study Group of Japan. Testing the
30
31 effectiveness of antiemetic guidelines: results of a prospective registry by the
32
33 CINV Study Group of Japan. *Int J Clin Oncol* 2015;20(5):855-65.
34
- 35
36 12. [https://www.mascc.org/assets/Guidelines-](https://www.mascc.org/assets/Guidelines-Tools/mascc_antiemetic_guidelines_english_v.1.5SEPT29.2019.pdf)
37
38 [Tools/mascc_antiemetic_guidelines_english_v.1.5SEPT29.2019.pdf](https://www.mascc.org/assets/Guidelines-Tools/mascc_antiemetic_guidelines_english_v.1.5SEPT29.2019.pdf) (accessed 7
39
40 Mar 2020).
41
- 42
43 13. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf (accessed
44
45 4 May 2020).
46
- 47
48 14. Hesketh PJ, Bohlke K, Kris MG, et al. Antiemetics: American Society of
49
50 Clinical Oncology Clinical Practice Guideline Update. *J Oncol Pract*
51
52 2017;13(12):825-830.
53
- 54
55 15. Bymaster FP1, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of
56
57 the atypical antipsychotic olanzapine. *Neuropsychopharmacology*
58
59 1996;14(2):87-96.
60

- 1
2
3
4
5
6 16. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of
7
8 Chemotherapy-Induced Nausea and Vomiting. *N Engl J Med* 2016;375(2):134-
9
10 42.
11
12
13 17. Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard
14
15 antiemetic therapy for the prevention of chemotherapy-induced nausea and
16
17 vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-
18
19 controlled, phase 3 trial. *Lancet Oncol* 2020;21(2):242-249.
20
21
22 18. Watts LM, Manchem VP, Leedom TA, et al. Reduction of hepatic and adipose
23
24 tissue glucocorticoid receptor expression with antisense oligonucleotides
25
26 improves hyperglycemia and hyperlipidemia in diabetic rodents without causing
27
28 systemic glucocorticoid antagonism. *Diabetes* 2005;54(6):1846-53.
29
30
31 19. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention
32
33 of chemotherapy-induced nausea and vomiting: a randomized phase III trial. *J*
34
35 *Support Oncol* 2011;9(5):188-95.
36
37
38 20. Miyaji T, Iioka Y, Kuroda Y, et al. Japanese translation and linguistic validation
39
40 of the US National Cancer Institute's Patient-Reported Outcomes version of the
41
42 Common Terminology Criteria for Adverse Events (PRO-CTCAE). *J Patient*
43
44 *Rep Outcomes* 2017;1(1):8.
45
46
47 21. Kawaguchi T, Azuma, K, Sano M, et al. The Japanese version of the National
48
49 Cancer Institute's patient-reported outcomes version of the common
50
51 terminology criteria for adverse events (PRO-CTCAE): psychometric validation
52
53 and discordance between clinician and patient assessments of adverse events. *J*
54
55 *Patient Rep Outcomes* 2017;2(1):2.
56
57
58
59
60

- 1
2
3
4
5
6 22. Kobayashi K, Takeda F, Teramukai S, et al. A cross-validation of the European
7
8 Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-
9
10 C30) for Japanese with lung cancer. *Eur J Cancer* 1998 ;34(6):810-5.
11
12
13 23. Yanai T, Iwasa S, Hashimoto H, et al. A double-blind randomized phase II dose-
14
15 finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis
16
17 induced by highly emetogenic cisplatin-based chemotherapy. *Int J Clin Oncol*
18
19 2018;23(2):382-388.
20
21
22 24. Nakashima K, Murakami H, Yokoyama K, et al. A Phase II study of
23
24 palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of
25
26 cisplatin-based chemotherapy-induced nausea and vomiting in patients with
27
28 thoracic malignancy. *Jpn J Clin Oncol* 2017;47(9):840-843.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure caption

Figure 1. The schedule of enrolment, interventions and assessments.

For peer review only

Minatogawa et al, Figure 1

TIMEPOINT	Enrolment	Enrolment	Post- enrolment							
	-8 days	0	day 1	day 2	day 3	day 4	day 5	day 6	day 7	day 8
ENROLMENT:										
Eligibility screen	X									
History and physical	X									
ECOG PS	X									
Laboratory studies	X									
Informed consent	X									
Enrolment		X								
INTERVENTIONS:										
Fosaprepitant (APR) administration			X	(X)	(X)					
PALO administration			X							
OLZ administration			X	X	X	X				
DEX administration			X							
DEX or placebo administration				X	X	X				
ASSESSMENTS:										
Risk factor		X								
PRO-CTCAE			X	X	X	X	X	X		
QOL		X								X
Presence of vomiting			X	X	X	X	X	X		
Nausea (NRS)			X	X	X	X	X	X		
Use of rescue medication			X	X	X	X	X	X		
CTCAE v4.0-JCOG			X	X	X	X	X	X		



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	5
	2b	All items from the World Health Organization Trial Registration Data Set	15
Protocol version	3	Date and version identifier	5
Funding	4	Sources and types of financial, material, and other support	17
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	17
	5b	Name and contact information for the trial sponsor	2-3
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	17
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	11

1	Introduction			
2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	6-8
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	6-8
7				
8	Objectives	7	Specific objectives or hypotheses	9
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	9
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	9
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	9-10
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	12-13
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	12-13
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	11
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	12-13
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	13-14
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
35			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
36			efficacy and harm outcomes is strongly recommended	
37				
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for SPIRIT figure	
39			participants. A schematic diagram is highly recommended (see Figure)	
40				
41				
42				
43				
44				
45				
46				

1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 14
2 clinical and statistical assumptions supporting any sample size calculations
3
4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 10
5
6
7
8
9 Methods: Assignment of interventions (for controlled trials)
10
11 Allocation:
12
13 Sequence 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 10
14 generation factors for stratification. To reduce predictability of a random sequence, details of any planned restriction
15 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants
16 or assign interventions
17
18 Allocation 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 10
19 concealment opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
20 mechanism
21
22 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 10
23 interventions
24
25
26 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 10-11
27 assessors, data analysts), and how
28
29 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's 10-11
30 allocated intervention during the trial
31
32
33 Methods: Data collection, management, and analysis
34
35 Data collection 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 11,13-14
36 methods processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of
37 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.
38 Reference to where data collection forms can be found, if not in the protocol
39
40
41
42
43
44
45
46

1		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	11
2				
3				
4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	11
5				
6				
7				
8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	14
9				
10				
11				
12		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	14
13				
14		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	14
15				
16				
17				
18	Methods: Monitoring			
19				
20	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	14
21				
22				
23				
24				
25		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	14
26				
27				
28	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	12
29				
30				
31				
32	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	11
33				
34				
35				
36	Ethics and dissemination			
37				
38	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	14-15
39				
40				
41				
42				
43				
44				
45				
46				

1	Protocol	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes,	14-15
2	amendments		analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals,	
3			regulators)	
4				
5	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and	14-15
6			how (see Item 32)	
7				
8		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary	NA
9			studies, if applicable	
10				
11	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained	11
12			in order to protect confidentiality before, during, and after the trial	
13				
14	Declaration of	28	Financial and other competing interests for principal investigators for the overall trial and each study site	16
15	interests			
16				
17				
18	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that	15
19			limit such access for investigators	
20				
21	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial	12
22	trial care		participation	
23				
24	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals,	14-15
25			the public, and other relevant groups (eg, via publication, reporting in results databases, or other data	
26			sharing arrangements), including any publication restrictions	
27				
28				
29		31b	Authorship eligibility guidelines and any intended use of professional writers	14-15
30				
31		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
32				
33				
34	Appendices			
35	Informed consent	32	Model consent form and other related documentation given to participants and authorised surrogates	NA
36	materials			
37				
38	Biological	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular	NA
39	specimens		analysis in the current trial and for future use in ancillary studies, if applicable	
40				
41				

1 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
2 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
3 [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](#) license.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

BMJ Open

Study protocol for SPARED trial: Randomized noninferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on day 1-4 combined with neurokinin-1 receptor antagonist, palonosetron, and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041737.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Sep-2020
Complete List of Authors:	<p>Minatogawa, Hiroko; St.Marianna University School of Medicine Hospital, Department of Pharmacy Izawa, Naoki; St. Marianna University School of Medicine, Department of Clinical Oncology Kawaguchi, Takashi; Tokyo University of Pharmacy and Life Sciences, Department of Practical Pharmacy Miyaji, Tempei; University of Tokyo, Shimomura, Kazuhiro; Aichi Cancer Center Hospital Kazunori, Honda; Aichi Cancer Center Hospital, Department of Clinical Oncology Iihara, Hirotooshi; Gifu University Hospital, Pharmacy Ohno, Yasushi; Gifu University School of Medicine Graduate School of Medicine, Department of Cardiology and Respiriology Inada, Yusuke; Yokohama Rosai Hospital, Department of Pharmacy Arioka, Hitoshi; Yokohama Rosai Hospital, Department of Medical Oncology Morita, Hajime; St. Marianna University Yokohama City Seibu Hospital, Department of Pharmacy Hida, Naoya; St.Marianna University School of Medicine, 12. Department of Internal Medicine Sugawara, Mitsuhiro; Kitasato University Hospital, 13. Department of Pharmacy Katada, Chikatoshi; Kitasato University School of Medicine, Department of Gastroenterology Nawata, Shuichi; Showa University Northern Yokohama Hospital, Department of Hospital Pharmaceutics Ishida, Hiroo; Showa University Northern Yokohama Hospital, Department of Internal Medicine Tsuboya, Ayako; Kawasaki Municipal Tama Hospital Tsuda, Takashi; St. Marianna University School of Medicine, Department of Clinical Oncology; Shonan Fujisawa Tokushukai Hospital, Department of Hepato-Biliary-Pancreatic Center Yamaguchi, Takuhiro; Tohoku University School of Medicine, Division of Biostatistics Nakajima, Takako; St. Marianna University School of Medicine, Department of Clinical Oncology,; Kyoto University Hospital, Division of Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Therapy
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Palliative care
Keywords:	CHEMOTHERAPY, Adult palliative care < PALLIATIVE CARE, Clinical trials < THERAPEUTICS, Adverse events < THERAPEUTICS





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7 **1 Title**
8
9

10 2 Study protocol for SPARED trial: Randomized noninferiority phase III trial comparing
11 3 dexamethasone on day 1 with dexamethasone on day 1–4, combined with neurokinin-1
12 4 receptor antagonist, palonosetron, and olanzapine (5 mg) in patients receiving
13 5 cisplatin-based chemotherapy
14
15
16
17
18
19
20
21
22
23

24 **7 Authors' name**
25

26 8 Hiroko Minatogawa¹, Naoki Izawa², Takashi Kawaguchi³, Tempei Miyaji⁴, Kazuhiro
27 9 Shimomura⁵, Kazunori Honda⁶, Hirotoshi Iihara⁷, Yasushi Ohno⁸, Yusuke Inada⁹,
28 10 Hitoshi Arioka¹⁰, Hajime Morita¹¹, Naoya Hida¹², Mitsuhiro Sugawara¹³, Chikatoshi
29 11 Katada¹⁴, Shuichi Nawata¹⁵, Hiroo Ishida¹⁶, Ayako Tsuboya¹⁷, Takashi Tsuda^{2,18},
30 12 Takuhiro Yamaguchi¹⁹, Takako Eguchi Nakajima^{2,20}
31
32
33
34
35
36
37
38
39

40 **14 Authors' affiliation**
41

- 42 15 1. Department of Pharmacy, St.Marianna University School of Medicine Hospital,
43 16 Kawasaki, Japan
44 17 2. Department of Clinical Oncology, St. Marianna University School of Medicine,
45 18 Kawasaki, Japan
46 19 3. Department of Practical Pharmacy, Tokyo University of Pharmacy and Life
47 20 Sciences, Tokyo, Japan
48 21 4. Department of Clinical Trial Data Management, Graduate School of Medicine, The
49 22 University of Tokyo, Tokyo, Japan
50
51
52
53
54
55
56
57
58
59
60

- 23 5. Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan
- 24 6. Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
- 25 7. Department of Pharmacy, Gifu University Hospital, Gifu, Japan
- 26 8. Department of Respiriology, Gifu University Graduate School of Medicine, Gifu,
27 Japan
- 28 9. Department of Pharmacy, Yokohama Rosai Hospital, Yokohama, Japan
- 29 10. Department of Medical Oncology, Yokohama Rosai Hospital, Yokohama, Japan
- 30 11. Department of Pharmacy, St. Marianna University Yokohama City Seibu Hospital,
31 Yokohama, Japan
- 32 12. Department of Internal Medicine, St. Marianna University School of Medicine,
33 Kawasaki, Japan
- 34 13. Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan
- 35 14. Department of Gastroenterology, Kitasato University School of Medicine,
36 Sagamihara, Japan
- 37 15. Department of Hospital Pharmaceutics, Showa University Northern Yokohama
38 Hospital, Yokohama, Japan
- 39 16. Department of Internal Medicine, Showa University Northern Yokohama Hospital,
40 Yokohama, Japan
- 41 17. Department of Pharmacy, St. Marianna University Kawasakishi Muncipal Tama
42 Hospital, Kawasaki, Japan
- 43 18. Department of Hepato-Biliary-Pancreatic Center, Shonan Fujisawa Tokushukai
44 Hospital, Fujisawa, Japan
- 45 19. Division of Biostatistics, Tohoku University School of Medicine, Sendai, Japan

1
2
3
4
5
6 46 20. Division of Kyoto Innovation Center for Next Generation Clinical Trials and iPS
7
8 47 Cell Therapy, Kyoto University Hospital, Kyoto, Japan
9

10
11 48

12
13 49 **Corresponding author**

14
15 50 Takako Eguchi Nakajima, M.D., Ph.D.

16
17 51 Division of Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell

18
19 52 Therapy, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku Kyoto,

20
21 53 606-8507, Japan

22
23 54 E-mail: tnakajima@kuhp.kyoto-u.ac.jp

24
25 55 Tel: +81-75-751-3111 (4756)

26
27 56 Fax: +81-75-751-4732

28
29 57

30
31 58 **Key words**

32
33 59 Nausea, Vomiting, Dexamethasone, Olanzapine, Cisplatin

34
35 60

36
37 61 **Word count**

38
39 62 3633 words

40
41 63
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 **64 ABSTRACT**
7
8

9 **65 Introduction**
10
11

12 66 Dexamethasone (DEX) is administered for multiple days to prevent
13
14 67 chemotherapy-induced nausea and vomiting (CINV) for patients receiving highly
15
16 68 emetogenic chemotherapy (HEC); however, its notorious side effects have been widely
17
18 69 reported. Although our multicenter randomized double-blind comparative study verified
19
20 70 noninferiority of sparing DEX after day 2 of chemotherapy when combined with
21
22 71 neurokinin-1 receptor antagonist (NK1-RA) and palonosetron (Palo) for patients
23
24 72 receiving HEC regimen, DEX sparing was not non-inferior in patients receiving
25
26 73 cisplatin (CDDP)-based HEC regimens in subgroup analysis. Recently, the efficacy of
27
28 74 the addition of olanzapine (OLZ) to standard triple antiemetic therapy on HEC has been
29
30 75 demonstrated by several phase III trials. This study aims to confirm noninferiority of
31
32 76 DEX sparing when it is combined with NK-1RA, Palo, and OLZ in patients receiving
33
34 77 CDDP-based HEC regimens.
35
36
37
38
39
40

41 **78 Methods and analysis**
42
43

44 79 This is a randomized, double-blind, phase III trial. Patients who are scheduled to receive
45
46 80 CDDP $\geq 50\text{mg}/\text{m}^2$ as initial chemotherapy are eligible. Patients are randomly assigned
47
48 81 to receive either DEX on day 1–4 or DEX on day 1 combined with NK1-RA, Palo, and
49
50 82 OLZ (5mg). The primary endpoint is complete response (CR) rate, defined as no emesis
51
52 83 and no rescue medications during the delayed phase (24 to 120 hours post-CDDP
53
54 84 administration). The noninferiority margin is set at -15.0%. We assume that CR rates
55
56 85 would be 75% in both arms. Two hundred sixty-two patients are required for at least
57
58
59
60

1
2
3
4
5
6 86 80% power to confirm noninferiority at a one-sided significance level of 2.5%. After
7
8 87 considering the possibility of attrition, we set our final required sample size of 280.
9

10
11
12 88 **Ethics and dissemination**
13

14
15 89 The institutional review board approved the study protocol at each of the participating
16
17 90 centers. The trial result will be presented at international conferences and published in
18
19 91 peer-reviewed journals.
20
21

22
23 92 **Trial registration number**
24

25
26 93 UMIN000032269
27
28

29
30 94 **Protocol version**
31

32
33 95 3.0, 24 May 2020.
34
35

36
37 96 **Strengths and limitations of this study**
38

- 39 97 ➤ This is the first trial to evaluate whether adding olanzapine to neurokinin-1 receptor
40
41 98 antagonist, palonosetron (Palo), and dexamethasone (DEX) can spare DEX
42
43 99 administration on day 2 to 4 for patients receiving cisplatin-based regimens.
44
45 100 ➤ This study is a multicenter, placebo-controlled, double-blinded, randomized phase
46
47 101 III study.
48
49
50
51 102 ➤ A limitation of this study is that it was conducted solely within the Japanese
52
53 103 population.
54
55

56
57 104
58
59
60

105 INTRODUCTION

106 Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent
107 adverse reactions associated with chemotherapy, and considerably reduces patient
108 quality of life (QOL). CINV has been traditionally assessed in overall (0-120 h
109 post-chemotherapy), acute (0-24 h post-chemotherapy), or delayed (24-120 h
110 post-chemotherapy) phases,[1]. Intravenously administered cytotoxic agents are
111 categorized into four emetic risk groups (high, moderate, low, and minimal),[2]. Highly
112 emetogenic chemotherapy (HEC) including cisplatin (CDDP)-based regimen and
113 anthracycline plus cyclophosphamide (AC) regimen can lead to a > 90 % incidence of
114 emesis in patients without an adequate antiemetic prophylaxis,[3]. When patients were
115 administered prophylactic antiemetics prior to HEC treatment, the incidence of emesis
116 (or requiring additional antiemetics) was found to be 35% according to a recent
117 study.[4].

118 Dexamethasone (DEX), 5-hydroxytryptamine type 3 receptor antagonists
119 (5-HT₃-RA) and neurokinin-1 receptor antagonists (NK1-RA) have been developed to
120 inhibit CINV from HEC,[5-6]. DEX is typically administered for multiple days from the
121 start of chemotherapy to care for delayed CINV,[7];whereas, frequent administration of
122 corticosteroids has been associated with many adverse effects such as insomnia,
123 hyperglycemia and reduced bone mineral density,[8-10]. Therefore,
124 corticosteroid-minimizing (DEX-sparing) strategies, which administer DEX in the acute
125 phase (day 1) and omit DEX in the delayed phase (day 2 and later), have been
126 evaluated,[11]. Our multicenter randomized double-blind comparative study (DEX-1
127 study) showed the complete response (CR; no emesis, no use of rescue medication) rate

1
2
3
4
5
6 128 in the overall phase of DEX on day 1 provided a non-inferior antiemetic efficacy to a
7
8 129 treatment of DEX on day 1-3 when combined with NK1-RA and palonosetron (Palo) for
9
10 130 patients receiving HEC including AC and CDDP-based regimen. (44.0 % vs. 46.9 %, P
11
12 131 = 0.007),[12]. In a subgroup analysis of patients receiving CDDP-based regimen, CR
13
14 132 rates of acute phase demonstrated a noninferiority of DEX on day 1 to day 1-3 (95.6 %
15
16 133 vs 95.6 %, $P = 0.007$); whereas, CR rates of the overall and delayed phases DEX on day
17
18 134 1 were lower than those DEX on day 1-3 (57.8 % vs 66.7 %, $P = 0.272$; 57.8 % vs
19
20 135 68.9 %, $P = 0.349$, respectively). However, the DEX-1 study was underpowered to
21
22 136 evaluate whether multiple days of DEX can be spared for CDDP-based regimens
23
24 137 because patients who received the CDDP-based regimen represented only 23% of the
25
26 138 total sample population,[13]. Therefore, the plausibility of DEX sparing in CDDP
27
28 139 remains inconclusive. Some guidelines still recommend multiple-days DEX in
29
30 140 combination with 5-HT₃-RA and NK1-RA for CDDP-based regimens,[3, 14-16].
31
32
33
34
35

36 141 Olanzapine (OLZ) is classified as a multi-acting receptor-targeted antipsychotic
37
38 142 and blocks dopamine receptors (D₁, D₂, D₄), 5-HT receptors (5-HT_{2A}, 5-HT_{2C}, 5-HT₃),
39
40 143 α_1 adrenergic receptors, histamine receptors, and multiple muscarine receptors,[17],
41
42 144 which might affect CINV. In the randomized, double-blind, phase III trial involving
43
44 145 patients receiving HEC regimens, it was more effective to combine OLZ 10mg than
45
46 146 placebo with NK1-RA, 5-HT₃-RA, and DEX for the prevention of nausea and vomiting
47
48 147 in acute and delayed phases,[4]; however, OLZ (10 mg) had excessive sedation.
49
50 148 Therefore, it is difficult to use OLZ 10 mg for all patients in practice setting. Recently,
51
52 149 J-FORCE study, which was a randomized, double-blind, placebo-controlled phase III
53
54 150 trial evaluating the significance of adding of 5 mg OLZ to NK1-RA, Palo, and DEX in
55
56 151 CDDP-based regimens, showed that significantly more patients receiving OLZ achieved
57
58
59
60

1
2
3
4
5
6 152 CR from delayed CINV compared with those who received placebo (79 % versus 66%,
7
8 153 $P < 0.001$); moreover, no differences were found between two groups in the incidence
9
10 154 of sedation,[18]. The addition of OLZ in combination with NK1-RA, Palo, and DEX
11
12
13 155 has greater benefit and becomes a standard antiemetic therapy in patients receiving
14
15 156 CDDP-based regimens.

16
17 157 Treatment with OLZ was associated with metabolic effects, including elevated
18
19 158 glucose concentrations manifesting as insulin resistance,[19]. A phase III study showed
20
21 159 that grade 3 hyperglycemia was observed more frequently in the OLZ versus placebo
22
23 160 group,[4]. Therefore, there is a concern that the combination of OLZ and multiple-days
24
25 161 DEX may worsen glucose intolerance. In another study, Navari et al. also demonstrated
26
27 162 that OLZ, combined with a single dose of DEX and Palo was very effective at
28
29 163 controlling acute and delayed phase CINV in patients receiving HEC; moreover, this
30
31 164 regimen was not associated with significant hyperglycemia,[20].
32
33
34

35 165 Based on these results, we speculate that the antiemetic regimen of OLZ 5mg,
36
37 166 NK1-RA, Palo, and a single dose of DEX could be effective and safe for delayed phase
38
39 167 CINV in patients receiving CDDP-based regimen. We planned this randomized,
40
41 168 double-blind, phase III trial to evaluate the noninferiority of DEX on day1 compared
42
43 169 with DEX on day1 to 4 when combined with NK1-RA, Palo, and OLZ in patients
44
45 170 receiving CDDP-based regimens.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 172 **METHODS AND ANALYSIS**
7

8
9 173 **Study design**
10

11
12 174 The Standard Protocol Items for Randomized Trials statement and checklist were
13
14 175 followed in preparing the protocol. This multicenter, placebo-controlled, double-blinded,
15
16 176 randomized, noninferiority, phase III study aims to confirm the noninferiority of DEX
17
18 177 on day 1 compared to DEX on days 1 to 4 combined with NK1-RA, Palo and OLZ 5mg
19
20 178 to prevent CINV in patients with solid malignant tumor receiving CDDP-based
21
22 179 regimens.
23
24
25
26
27
28
29

30
31 181 **Study setting and participants**
32

33
34 182 Recruiting will be performed in 10 sites across Japan. The inclusion and exclusion
35
36 183 criteria are summarized in box 1.
37
38
39

40 184

41
42
43 185 Box.1
44

45 186
46
47

48 187 **Inclusion criteria**
49

- 50 188 I. Patients with malignant tumor, excluding those with hematologic malignancies or
51
52 189 those receiving first-line treatment with CDDP $\geq 50\text{mg/m}^2$ (previous use of
53
54 190 moderate or low emetic chemotherapy is permitted).
55
56
57 191 II. Age: 20–74 years at the time of enrollment.
58
59
60

- 1
2
3
4
5
6 192 III. Absence of nausea and vomiting within 24 hours prior to registration.
7
8 193 IV. Eastern Cooperative Oncology Group performance status of 0–1.
9
10 194 V. Meeting the following standard values of general clinical tests within 2 weeks prior
11
12 to enrollment:
13
14 a. alanine aminotransferase < 100 IU/L.
15
16 b. aspartate aminotransferase < 100 IU/L.
17
18 c. total bilirubin < 2.0 mg/dL.
19
20 d. serum creatinine < 1.5 mg/dL.
21
22
23 200 VI. Patients with an expected prognosis of 3 months or more.
24
25
26 201 VII. Patients who provided written informed consent.
27
28
29
30

31 **203 Exclusion criteria**

- 32
33 204 I. Patients undergoing systemic glucocorticoid therapy.
34
35 205 II. Patients using antiemetics other than the trial drug.
36
37 206 III. Patients receiving moderately emetogenic chemotherapy within 6 days before and
38
39 after CDDP administration.
40
41
42 208 IV. Patients who cannot be hospitalized until after 120 hours of starting CDDP
43
44 administration as the study requires daily use of an electronic patient reported
45
46 outcome (ePRO) system.
47
48
49 211 V. Patients receiving radiation therapy for the abdomen or pelvis within 6 days prior to
50
51 registration until 6 days after CDDP administration.
52
53 213 VI. Patients with diabetes mellitus receiving treatment with insulin and/ or oral
54
55 hypoglycemic agents or patients with HbA1c (NGSP) >6.5 % (>6.1 % in the event
56
57 of JDS).
58
59
60

1
2
3
4
5
6 216 VII. Patients with symptomatic brain metastasis, convulsive disorder requiring treatment
7
8 217 with anticonvulsants, and mental illness or psychiatric symptoms that impede
9
10 218 activities of daily life.

11
12
13 219 VIII. Patients who are incapable of taking oral agents.

14
15 220 IX. Patients with a history of allergy to study drugs or similar compounds.

16
17 221 X. Breastfeeding women, pregnant women, or patients not willing to use
18
19 222 contraception.

20
21 223 XI. Patients deemed ineligible for the study by the investigator (e.g., patients who are
22
23 224 unable to maintain medication adherence or who may experience difficulty using
24
25 225 electronic devices).

26
27
28
29
30 226

31
32
33 227 The main inclusion criterion is patients who are eligible in the study are 20 to 74 years
34
35 228 old with malignant tumor, excluding hematological malignancies, receiving first-line
36
37 229 treatment with CDDP ≥ 50 mg/m² (previous use of moderately or low emetogenic
38
39 230 chemotherapy is permitted). The main exclusion criteria are as follows: (1) presence of
40
41 231 systemic glucocorticoid therapy; (2) patients using antiemetics other than the trial drug;
42
43 232 (3) patients receiving moderately emetogenic chemotherapy within 6 days before and
44
45 233 after CDDP administration (Minimally to low emetogenic agents are allowed); (4)
46
47 234 patients receiving radiation therapy to abdomen or pelvis within 6 days prior to
48
49 235 enrollment until 6 days after CDDP; (5) patients with symptomatic brain metastasis,
50
51 236 diabetes mellitus, and convulsive disorder; and (6) patients who are incapable of taking
52
53 237 oral agents.

54
55
56
57
58
59 238
60

1
2
3
4
5
6 239 **Recruitment, randomization, masking, and follow-up**
7

8
9 240 Recruitment
10

11
12
13 241 Eligible patients satisfying the screening inclusion and exclusion criteria will be invited
14
15 242 to participate in the study by site investigators.
16

17
18
19 243

20
21
22 244 Randomization
23

24
25 245 Physicians will introduce the trial to patients. On enrollment and after providing
26
27 246 informed consent, Eligible patients will be randomly assigned to receive either DEX on
28
29 247 day 1 to 4 or DEX on day 1 with placebo on days 2 to 4 as part of prophylactic
30
31 248 antiemetic therapy. Randomization is centrally performed by random allocation
32
33 249 modules of electronic data captures (EDC) using the minimization method with
34
35 250 balancing prognostic factors for age (< 60 vs ≥ 60 years), sex, CDDP dose level (\geq
36
37 251 $70\text{mg}/\text{m}^2$ vs $< 70\text{mg}/\text{m}^2$), and institution.
38
39
40

41
42
43 252

44
45
46 253 Masking
47

48
49 254 Patients and clinicians responsible for treatment will be blinded to administration of
50
51 255 DEX or placebo. Only an unblinded pharmacist who prepares the study drug, but is not
52
53 256 involved in patient care will know the assignment and outcome. All study drugs will be
54
55 257 prepared by this pharmacist. As a rule, no data will be disclosed until fixed. However,
56
57 258 during the trial period, when it is considered necessary to know the details of the trial
58
59
60

1
2
3
4
5
6 259 drug to ensure participant safety, such as for serious adverse events, the study
7
8 260 representative and study secretariat will make an inquiry to and discuss the need for
9
10 261 disclosure with the Efficacy and Safety Evaluation Committee. When disclosure is
11
12 262 deemed necessary as a result of this consultation, the details will be communicated to
13
14 263 the study secretariat, and the details of the trial drug will be disclosed.
15
16
17
18
19
20
21

264

265 **Data management, central monitoring, and auditing**

266 The data center is located in the Department of Clinical Trial Data Management,
267 Graduate School of Medicine, Tokyo University, Tokyo, Japan. Enrollment,
268 randomization, data collection, and monitoring will be performed using EDC system
269 Viedoc 4 and Viedoc me (Viedoc Technologies). Data entry to the electronic case report
270 form is performed by investigators using EDC at each site. Patient-Reported Outcomes
271 (PRO) data are collected electronically from patients through an electronic tablet device.
272 No personally identifiable information is entered into the EDC, and the data center does
273 not collect personal information. The central monitoring will be conducted by the data
274 center, and monthly and semi-annually monitoring reports will be disseminated to
275 investigators to inform about the trial progress and discuss data quality-related issues.
276 The protocol review committee and independent Data Monitoring Committee will
277 assess the protocol amendments, serious adverse events reports, and monitoring reports
278 and provide any necessary recommendation to investigators. Auditing will be conducted
279 as necessary in this study.

280

1
2
3
4
5
6 281 Harms

7
8
9 282 Investigators must record all adverse events in the medical records and web systems.

10 283 The Common Terminology Criteria for Adverse Events (CTCAE, v4.0) will be used to

11 284 grade each adverse event. In conjunction with the CTCAE to grade adverse events, the

12 285 Patient Reported Outcomes CTCAE (PRO-CTCAE) will be also administered to

13 286 patients for their completion to complement information about subjective symptoms.

14 287 All adverse events are to be followed up continually during the course of treatment. All

15 288 severe adverse events must be reported to the institutional review board (IRB) and

16 289 reported to investigators in all sites and discussed through a mail. Patients who are

17 290 enrolled into the study will be treated by the health care services that are provided by

18 291 their health insurance.

19 292

20
21
22
23
24
25
26
27
28
29
30
31
32
33 293 **Treatment**

34 294 All patients receive Palo (0.75 mg intravenous infusion on day 1 at 30 min before the

35 295 start of chemotherapy), NK1-RA (aprepitant 125 mg oral administration on day1 and 80

36 296 mg on days 2 and 3, or fosaprepitant 150 mg intravenous infusion on day 1 at 1 hour

37 297 before the start of chemotherapy), and OLZ (5mg oral administration on days 1 to 4

38 298 after dinner). DEX is administered as follows: patients in both arms receive DEX 9.9

39 299 mg intravenous infusion on day 1; patients receive DEX 6.6 mg or placebo intravenous

40 300 infusion on days 2 to 4. When using fosaprepitant, the dose level is increased on days 3

41 301 and 4 due to interaction with DEX up to day 2, therefore patients receive an intravenous

42 302 DEX 13.2 mg or placebo on days 3 and 4. Patients were allowed to take rescue

1
2
3
4
5
6 303 medication throughout the study period for nausea or vomiting, if necessary. The choice
7
8 304 of recommended rescue is determined by each investigator from among
9
10 305 prochlorperazine, metoclopramide, domperidone, chlorpheniramine, alprazolam,
11
12 306 lorazepam, and haloperidol.
13
14
15
16 307

19 308 **Study endpoints**

20
21
22
23 309 The primary endpoint is CR rate (no emesis and no rescue medications) during the
24
25 310 delayed phase (24 to 120 hours post-CDDP administration). Secondary endpoints are as
26
27 311 follows: (1) CR rate during the acute phase (24 hours post-CDDP administration) and
28
29 312 the overall phase (120 hours post-CDDP administration); (2) complete control (no
30
31 313 emesis, no rescue use, and no significant nausea) rate; (3) total control (no emesis, no
32
33 314 rescue use, and no nausea) rate; (4) no emesis rate and no nausea rate in the overall,
34
35 315 acute, and delayed phase; (5) time to treatment failure (i.e., time to first emesis or using
36
37 316 rescue, whichever occurred first); and (6) severity of nausea during the overall phase.
38
39 317 Adverse events are associated with antiemetic therapy (CTCAE v4.0 Japanese Clinical
40
41 318 Oncology Group [JCOG] version and the PRO-CTCAE v1.0.).
42
43
44
45
46
47

48 320 **Outcome assessments**

49
50 321 Figure 1 provides details of the schedule of enrollment, interventions, and assessments.
51
52 322 Presence of emesis and severity of nausea will be assessed by patients using a 2-point
53
54 323 categorical scale and 11-point numerical rating scale (NRS), respectively. Significant
55
56 324 nausea is defined as 3 points or greater on the NRS. The use of rescue medications will
57
58 325 be assessed by pharmacists.
59
60

1
2
3
4
5
6 326 Adverse events will be evaluated according to the CTCAE v4.0 (JCOG) version,
7
8 327 and the PRO-CTCAE v1.0. The Japanese version of PRO-CTCAE is linguistically and
9
10 328 psychometrically validated,[21-22]. QOL will be assessed by the European
11
12 329 Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30
13
14 330 (EORTC QLQ-C30) v.3 that is also validated in the Japanese version,[23].
15
16

17 331 Patients are asked to assess QOL before CDDP administration and on day 8, with
18
19 332 emesis and nausea assessed the PRO-CTCAE every 24 hours until 120 hours after
20
21 333 CDDP administration. The data from the PRO-CTCAE are assessed electronically using
22
23 334 a tablet device in the hospital setting, except for QOL on day 8, which is assessed on
24
25 335 paper-based questionnaire at home. The PRO-CTCAE data will be not reviewed by the
26
27 336 site investigators during the protocol treatment.
28
29
30

31 337

34 338 **Statistical analysis**

35
36
37 339 Sample size calculation is based on an analysis of the primary endpoint. In previous
38
39 340 studies with OLZ added to conventional antiemetic treatment for CDDP,[20, 24-25], the
40
41 341 delayed phase CR rate ranged from 75% to 85 %, therefore we expect that CR rate in
42
43 342 the delayed phase would be 75% in both arms. The noninferiority margin is set at
44
45 343 -15.0%. Two hundred sixty-two patients are required for at least 80 % power to confirm
46
47 344 noninferiority at a one-sided significance level of 2.5 %. After considering the
48
49 345 possibility of attrition we set our final required sample size of 280. Point estimates and
50
51 346 confidence intervals for the CR rate will be calculated and will be compared between
52
53 347 groups by using the Mantel-Haenszel test with adjustment for allocation factors. Interim
54
55 348 analysis is not planned. We will use a full analysis set. It consists of the registered
56
57
58
59
60

1
2
3
4
5
6 349 participant population who received at least a part of the protocol treatment; however,
7
8 350 participants who were deemed as ineligible for the study after registration and those
9
10 351 who were not administered CDDP-based regimens will be excluded from the analysis
11
12 352 set. For the primary analysis, we will impute non-CR for missing primary endpoints.
13
14
15
16 353

19 354 **Patient and public involvement**

22
23 355 Patients and/or public were not involved in the design of this study.
24
25 356

27 357 **Ethics and dissemination**

30
31 358 All patients will be required to provide written informed consent (supplement 1). The
32
33 359 study will be performed in accordance with the Declaration of Helsinki and Ethical
34
35 360 Guidelines for Medical and Health Research Involving Human Subjects published by
36
37 361 Japan's Ministry of Education, Science, and Technology and the Ministry of Health,
38
39 362 Labour, and Welfare and the modified Act on the Protection of Personal Information.
40
41 363 The protocol was approved by the IRB at each study site. This trial has been registered
42
43 364 at the University Hospital Medical Information Network (UMIN) Clinical Trials
44
45 365 Registry as UMIN000032269. Modifications in the study protocol will be
46
47 366 communicated to the IRB at each study site as well as to the protocol review committee.
48
49 367 Each Ethics Committee or IRB will revise informed consent materials given to
50
51 368 participants and adapt the informed consent according to their own institution's
52
53 369 guidelines. The main result will be presented at an international conference and
54
55
56
57
58
59
60

1
2
3
4
5
6 370 published in an English journal. Authorship will be ascribed in accordance with the
7
8 371 International Committee of Medical Journal Editors guidance.
9

10
11
12 372

13
14
15 373 **Access to data**

16
17
18 374 Only clinical data managers at the central data center have access to collected data
19
20 375 through the EDC system during the study. Site investigators have access to case data
21
22 376 within their institutions. After study closure, final dataset and related materials will be
23
24 377 archived in UMIN Individual Case Data Repository.
25
26
27

28
29 378

30
31
32 379 **Participating institutions**

33
34 380 St. Marianna University School of Medicine Hospital, St. Marianna University
35
36 381 Kawasakishi Muncipal Tama Hospital, St. Marianna University Yokohama City Seibu
37
38 382 Hospital, Showa University Northern Yokohama Hospital, Yokohama Rosai Hospital,
39
40 383 Nippon Medical School Musashi Kosugi Hospital, Aichi Cancer Center Hospital, Gifu
41
42 384 University Hospital, Kitasato University Hospital, Shizuoka Cancer Center.
43
44

45
46 385

47
48 386 **Trial status**

49
50 387 This protocol was approved by the Ethics Committee (approval ID 4035) of St.
51
52 388 Marianna University School of Medicine on July 27, 2018. The trial started in October
53
54 389 2018 and 183 subjects were randomized by May 2020. The recruitment is scheduled to
55
56 390 be completed in March 2021.
57
58
59
60

391

392 Confidentiality

393 Data will be retained in accordance with the Japanese ethical guidelines for clinical
394 research. Participants will be allocated a unique identification (ID) number at entry. The
395 master list linking participant personal information and ID number will be managed at
396 each institution. Data will be analyzed by ID number only. Records will be retained for
397 5 years after study completion and then will be destroyed at each institution.

398

399 Acknowledgments

400 We are grateful for support from the Japan Agency for Medical Research and
401 Development, Grant-in-Aid for Scientific Research. The authors thank in advance all
402 the patients, investigators and institutions involved in this study.

403

404 Authors' contributions

405 HM, NI and T.EN contributed to the trial conception and are the principal investigators.
406 HM, NI, TK, TM, TY, and T.EN participated in the design of the study. TY played a
407 primary role in designing statistical analysis. TK and TM played a primary role in
408 designing the data management approach. HM, NI, KS, KH, HI, YO, YI, HA, HM, NH,
409 MS, CK, SN, HI, AT, and TT have carried out recruitment and collected the data. Data
410 analysis and interpretation will be conducted by HM, NI, TK, TM, TY, and T.EN. HM
411 and NI wrote the first draft of the manuscript. All authors have read, approved the paper
412 and meet the criteria for authorship as established by the International Committee of
413 Medical Journals Editors.

414

1
2
3
4
5
6 415 **Funding**

7
8 416 This study is supported by Japan Agency for Medical Research and Development
9
10 417 (AMED) grant number 19ck0106501h0001. AMED had and will have no involvement
11
12 418 in the design and conduct of the study, collection, management, analysis, and
13
14 419 interpretation of the data; and preparation, review, or approval of the manuscript.
15
16

17 420

18
19 421 **Competing interests**

20
21 422 Author N.I has received honoraria from Takeda Pharma CO., Ltd, Eli Lilly, Japan, Ono
22
23 423 Pharma CO., Ltd, and Daiichi Sankyo Company. Author H.A has received grant from
24
25 424 Taiho, Chugai and Nippon Kayaku; personal fees from Novartis, Sanofi, Ono, Kyowa
26
27 425 Kirin and Takeda. Author T.Y has received grant and personal fees from ONO
28
29 426 PHARMACEUTICAL CO., LTD. Author. T.EN has received grant and personal fee
30
31 427 from Taiho Pharmaceutical Co., Chugai Pharmaceutical Co., Takeda Pharmaceutical
32
33 428 Co., Sanofi K.K., Daiichi Sankyo Co., Eli Lilly Japan K.K., Nippon Kayaku Co., Ono
34
35 429 Pharmaceutical Co. and MSD K.K.; personal fees from Mochida Pharmaceutical,
36
37 430 Celltrion Healthcare Japan, Merck Serono Co., Sawai Pharmaceutical Co., Bayer
38
39 431 Yakuhin, Bristol-Myers Squibb, Teijin Pharma, Pfizer Japan Inc., Novartis Japan,
40
41 432 Yakult Honsha Co. and Nipro Co; grant from Astellas Pharma Inc., Sumitomo
42
43 433 Dainippon Pharma Co., Eisai Co and Solasia Pharma K.K.. The other authors have
44
45 434 declared no conflicts of interest.
46
47
48
49
50

51 435
52
53
54
55
56
57
58
59
60

436 **REFERENCES**

- 437 1. Navari RM, Aapro M. antiemetic prophylaxis for chemotherapy-induced nausea
438 and vomiting. *N Engl J Med* 2016;374:1356–67.
- 439 2. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute
440 emetogenicity of cancer chemotherapy. *J Clin Oncol* 1997;15:103–9.
- 441 3. Japan Society of Clinical Oncology. Antiemetic guidelines for the treatment of
442 chemotherapy-induced nausea and vomiting: Kanehara shuppan 2015
- 443 4. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of
444 chemotherapy-induced nausea and vomiting. *N Engl J Med* 2016;375:134–42.
- 445 5. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist
446 aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a
447 multinational, randomized, double-blind, placebo-controlled trial in patients
448 receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. *J Clin*
449 *Oncol* 2003;21:4112–9.
- 450 6. Gralla RJ, de Wit R, Herrstedt, et al. Antiemetic efficacy of the neurokinin-1
451 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients
452 receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin:
453 analysis of combined data from two Phase III randomized clinical trials. *Cancer*
454 2005;104:864–8.
- 455 7. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer
456 chemotherapy: dosing, efficacy, and tolerability analysis. *Ann Oncol*
457 2007;18:233–40.

- 1
2
3
4
5
6 458 8. J Vardy, Chiew KS, Galica J, et al. Side effects associated with the use of
7
8 459 dexamethasone for prophylaxis of delayed emesis after moderately emetogenic
9
10 460 chemotherapy. *Br J Cancer* 2006;94:1011–5.
11
12
13 461 9. Jeong Y, Han HS, Lee HD, et al. A pilot study evaluating steroid-induced
14
15 462 diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer
16
17 463 patients. *Cancer Res Treat* 2016;48:1429–37.
18
19
20 464 10. Nakamura M, Ishiguro A, Muranaka T, et al. Prospective observational study on
21
22 465 effect of short-term periodic steroid premedication on bone metabolism in
23
24 466 gastrointestinal cancer (ESPRESSO-01). *Oncologist* 2017;22:592–600.
25
26
27 467 11. Celio L, Bonizzoni E, Zattarin E, et al. Impact of dexamethasone-sparing
28
29 468 regimens on delayed nausea caused by moderately or highly emetogenic
30
31 469 chemotherapy: a meta-analysis of randomised evidence. *BMC Cancer*
32
33 470 2019;19:1268.
34
35
36 471 12. Ito Y, Tsuda T, Minatogawa H, et al. Placebo-controlled, double-blinded phase
37
38 472 III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3
39
40 473 with combined neurokinin-1 receptor antagonist and palonosetron in
41
42 474 high-emetogenic chemotherapy. *J Clin Oncol* 2018;36:1000–6.
43
44
45 475 13. Celio L, Bonizzoni E, Aapro M. Is the dexamethasone-sparing strategy ready for
46
47 476 cisplatin? too early for an answer. *J Clin Oncol* 2018;36:2741–2.
48
49 477 14. https://www.mascc.org/assets/Guidelines-Tools/mascc_antiemetic_guidelines_english_v.1.5SEPT29.2019.pdf (accessed 7 Mar 2020).
50
51 478
52
53 479 15. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf (accessed
54
55 480 4 May 2020).
56
57
58
59
60

- 1
2
3
4
5
6 481 16. Hesketh PJ, Bohlke K, Kris MG, et al. Antiemetics: American Society of
7
8 482 Clinical Oncology Clinical Practice Guideline Update. *J Oncol Pract*
9
10 483 2017;13:825–30.
11
12 484 17. Bymaster FP1, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of
13
14 485 the atypical antipsychotic olanzapine. *Neuropsychopharmacology* 1996;14:87–
15
16 486 96.
17
18 487 18. Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard
19
20 488 antiemetic therapy for the prevention of chemotherapy-induced nausea and
21
22 489 vomiting (J-FORCE): a multicentre, randomised, double-blind,
23
24 490 placebo-controlled, phase 3 trial. *Lancet Oncol* 2020;21:242–9.
25
26 491 19. Watts LM, Manchem VP, Leedom TA, et al. Reduction of hepatic and adipose
27
28 492 tissue glucocorticoid receptor expression with antisense oligonucleotides
29
30 493 improves hyperglycemia and hyperlipidemia in diabetic rodents without causing
31
32 494 systemic glucocorticoid antagonism. *Diabetes* 2005;54:1846–53.
33
34 495 20. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention
35
36 496 of chemotherapy-induced nausea and vomiting: a randomized phase III trial. *J*
37
38 497 *Support Oncol* 2011;9:188–95.
39
40 498 21. Miyaji T, Iioka Y, Kuroda Y, et al. Japanese translation and linguistic validation
41
42 499 of the US National Cancer Institute’s Patient-Reported Outcomes version of the
43
44 500 Common Terminology Criteria for Adverse Events (PRO-CTCAE). *J Patient*
45
46 501 *Rep Outcomes* 2017;1:8.
47
48 502 22. Kawaguchi T, Azuma, K, Sano M, et al. The Japanese version of the National
49
50 503 Cancer Institute’s patient-reported outcomes version of the common
51
52 504 terminology criteria for adverse events (PRO-CTCAE): psychometric validation
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 505 and discordance between clinician and patient assessments of adverse events. *J*
7
8 506 *Patient Rep Outcomes* 2017;2:2.
9
10 507 23. Kobayashi K, Takeda F, Teramukai S, et al. A cross-validation of the European
11
12 508 Organization for Research and Treatment of Cancer QLQ-C30 (EORTC
13
14 509 QLQ-C30) for Japanese with lung cancer. *Eur J Cancer* 1998;34:810–5.
15
16
17 510 24. Yanai T, Iwasa S, Hashimoto H, et al. A double-blind randomized phase II
18
19 511 dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis
20
21 512 induced by highly emetogenic cisplatin-based chemotherapy. *Int J Clin Oncol*
22
23 513 2018;23:382–8.
24
25
26 514 25. Nakashima K, Murakami H, Yokoyama K, et al. A phase II study of
27
28 515 palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of
29
30 516 cisplatin-based chemotherapy-induced nausea and vomiting in patients with
31
32 517 thoracic malignancy. *Jpn J Clin Oncol* 2017;47:840–3.
33
34
35 518

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

519 Figure caption

520 Figure 1. The schedule of enrollment, interventions and assessments.

For peer review only

Minatogawa et al, Figure 1

TIMEPOINT	Enrolment	Enrolment	Post- enrolment							
	-8 days	0	day 1	day 2	day 3	day 4	day 5	day 6	day 7	day 8
ENROLMENT:										
Eligibility screen	X									
History and physical	X									
ECOG PS	X									
Laboratory studies	X									
Informed consent	X									
Enrolment		X								
INTERVENTIONS:										
Fosaprepitant (APR) administration			X	(X)	(X)					
PALO administration			X							
OLZ administration			X	X	X	X				
DEX administration			X							
DEX or placebo administration				X	X	X				
ASSESSMENTS:										
Risk factor		X								
PRO-CTCAE			X	X	X	X	X	X		
QOL		X								X
Presence of vomiting			X	X	X	X	X	X		
Nausea (NRS)			X	X	X	X	X	X		
Use of rescue medication			X	X	X	X	X	X		
CTCAE v4.0-JCOG			X	X	X	X	X	X		

Consent Form

St. Marianna University School of Medicine Hospital

Dear Hospital Director:

Title of the study: Randomized noninferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on day 1-4 combined with neurokinin-1 receptor antagonist, palonosetron, and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy

Description

1. Introduction about clinical trials.
2. The purpose of this study.
3. The method of this study.
4. The expected duration of participation in this study.
5. The expected number of participants in this study.
6. The expected effects of the medication under investigation and the possible side effects.
7. If you do not use this medication, other treatment options are available.
8. Participation in this study is voluntary.
9. If you agree to participate in the study, it requires observation of your first 5 days of chemotherapy.
10. Potential harmful effects to your health, which may occur during this study.
11. The chance that we may stop using this medication.
12. If you participate in this study, your medical records and other information may be examined during and after this study.
13. Your identity will not be revealed if the results of this study are made public.
14. We will keep you informed regarding this medication.
15. Your cost burden.
16. Information regarding the bioethics committee.
17. The institution participating in the study.
18. Information about your physician and consultation.

[Patient's signature line]

I have been fully informed of the above information, have received the letter of consent, and fully understand the details of this study. I voluntarily consent to participate in this study.

Date of consent: _____

Patient's name: (Signed) _____

[Physician's signature line]

1
2
3
4
5
6 I have fully briefed the patient on this clinical trial.

7 Date of presentation: _____

8 Affiliation: _____

9 Name: (Signed) _____

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	5
	2b	All items from the World Health Organization Trial Registration Data Set	17
Protocol version	3	Date and version identifier	5
Funding	4	Sources and types of financial, material, and other support	20
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1-3, 19
	5b	Name and contact information for the trial sponsor	3
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	20
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	13

1	Introduction			
2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	6-8
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	6-8
7				
8	Objectives	7	Specific objectives or hypotheses	8
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	9
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	9,18
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	9-11
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	14-15
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	12-13
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	13
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	14-15
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	15-16
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
35			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
36			efficacy and harm outcomes is strongly recommended	
37				
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	15, figure 1
39			participants. A schematic diagram is highly recommended (see Figure)	
40				
41				
42				
43				
44				
45				
46				

1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 16
2 clinical and statistical assumptions supporting any sample size calculations
3
4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 18
5
6
7
8
9 Methods: Assignment of interventions (for controlled trials)
10
11 Allocation:
12
13 Sequence generation 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 12
14 factors for stratification. To reduce predictability of a random sequence, details of any planned restriction
15 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants
16 or assign interventions
17
18 Allocation concealment mechanism 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 12
19 opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
20
21 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 12
22 interventions
23
24 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 12
25 assessors, data analysts), and how
26
27 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's 12-13
28 allocated intervention during the trial
29
30
31
32
33 Methods: Data collection, management, and analysis
34
35 Data collection methods 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 15-16
36 processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of
37 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.
38 Reference to where data collection forms can be found, if not in the protocol
39
40
41
42
43
44
45
46

1		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
2				
3				
4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	13
5				
6				
7				
8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	16-17
9				
10				
11				
12		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	16-17
13				
14		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	16-17
15				
16				
17				
18	Methods: Monitoring			
19				
20	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	13
21				
22				
23				
24				
25		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	13
26				
27				
28	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	14
29				
30				
31				
32	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	13
33				
34				
35				
36	Ethics and dissemination			
37				
38	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17
39				
40				
41				
42				
43				
44				
45				
46				

1	Protocol	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes,	17
2	amendments		analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals,	
3			regulators)	
4				
5	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and	17
6			how (see Item 32)	
7				
8		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary	NA
9			studies, if applicable	
10				
11	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained	13
12			in order to protect confidentiality before, during, and after the trial	
13				
14	Declaration of	28	Financial and other competing interests for principal investigators for the overall trial and each study site	20
15	interests			
16				
17				
18	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that	18
19			limit such access for investigators	
20				
21	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial	14
22	trial care		participation	
23				
24	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals,	17-18
25			the public, and other relevant groups (eg, via publication, reporting in results databases, or other data	
26			sharing arrangements), including any publication restrictions	
27				
28				
29		31b	Authorship eligibility guidelines and any intended use of professional writers	18
30				
31		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
32				
33	Appendices			
34				
35	Informed consent	32	Model consent form and other related documentation given to participants and authorised surrogates	17, supplement 1
36	materials			
37				
38	Biological	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular	NA
39	specimens		analysis in the current trial and for future use in ancillary studies, if applicable	
40				
41				

1 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
2 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
3 “Attribution-NonCommercial-NoDerivs 3.0 Unported” license.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only